Luxa Biotechnology, a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute in Rensselaer, New York, announced receipt of a $4 million grant from the California Institute for Regeneration Medicine to support the ongoing Phase 1/2a study of RPESC-RPE-4W transplantation for the treatment of dry age-related macular degeneration.
